Can tirzepatide (glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist) cause acid indigestion?
Granger CB, Alexander JH, McMurray JJV, et al
Cardiovascular Protection Studies Research reveals comprehensive cardiac protection including prevention of heart failure, normalization of elevated endothelin levels, and reduced long-term effects following myocardial infarction
Visit for further information including safety information
Trial identifiers appear on each card, showing the specific clinical trial and NCT number that the data comes from
Early signs tirzepatide is working may include: reduced hunger fewer cravings eating smaller portions naturally improved fullness after meals steady weight reduction Visible fat loss often becomes more noticeable after several weeks to a few months of consistent treatment